Biologic & Biosimilar RA Drugs Market Report 2026

Biologic & Biosimilar RA Drugs Market Overview

• Biologic & Biosimilar RA Drugs market size has reached to $14.57 billion in 2025 • Expected to grow to $20.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Increasing Healthcare Spending Is Anticipated To Fuel The Biologic & Biosimilar Ra Drugs Market • Market Trend: Biosimilar Treatment To Provide An Affordable Alternative • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biologic & Biosimilar RA Drugs Market?

Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis. The main sources of biologic & biosimilar RA drugs are microbial, mammalian, and others. Microbial sources refer to sources such as bacteria, yeast, and fungi. The various diseases involved are oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others whose drugs are manufactured by outsourced and in-house. They are sold by prescription drugs, and over-the-counter (OTC) drugs in hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Biologic & Biosimilar RA Drugs Market Growth Forecast?

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $20.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing adoption of biosimilars, technological advancements in drug delivery, expansion of manufacturing capacities, regulatory support for biologics, increasing awareness of precision medicine. Major trends in the forecast period include personalized biologic therapies, biosimilar adoption acceleration, advanced drug delivery systems, regulatory harmonization for biologics, cost optimization in ra treatments.

Global Biologic & Biosimilar RA Drugs Market Segmentation

1) By Source: Microbial, Mammalian, Other Sources 2) By Manufacturing: Outsourced, In-House 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources 2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines 3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Is The Driver Of The Biologic & Biosimilar RA Drugs Market?

The increasing healthcare spending is expected to propel the growth of the biologic & biosimilar RA drug market going forward. Healthcare spending refers to the total monetary investment made by individuals, governments, and organizations in medical goods and services, encompassing expenses related to the prevention, treatment, and management of health conditions. The use of biologic and biosimilar RA drugs optimizes rheumatoid arthritis management, balancing efficacy and cost-effectiveness in the provision of specialized and often expensive treatments required in healthcare spending. For instance, in November 2023, according to the CIHI, a Canada-based Institute for Health Information health company, the total health spending in Canada is expected to reach $344 billion in 2023, or $8,740 per Canadian, which is a 2.8% increase in 2023, after a mere 1.5% growth in 2022. Therefore, the increasing healthcare spending is driving the biologic & biosimilar RA drug industry.

Key Players In The Global Biologic & Biosimilar RA Drugs Market

Major companies operating in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Global Biologic & Biosimilar RA Drugs Market Trends and Insights

Major companies operating in the biologic & biosimilar RA drugs market are focusing on developing innovative solutions, such as dual-concentration biosimilar formulations, to meet the rising demand for affordable, accessible, and patient-friendly alternatives to high-cost biologics. Dual-concentration biosimilar options offer both high- and low-strength formulations that mirror branded biologics, enabling seamless treatment continuity and improved patient convenience compared with traditional single-concentration biologics. For instance, in July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company, launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. Available in high and low concentrations, HADLIMA aims to enhance access and affordability for patients with autoimmune diseases. The biosimilar is priced at an 85% discount to Humira, contributing to expanded patient access. HADLIMA includes an autoinjector, recognized by the Arthritis Foundation, and a patient support program, HADLIMA For You, offering educational resources and co-pay support. It is indicated for various conditions, including rheumatoid arthritis and Crohn's disease. HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), providing patients with seamless continuity of care.

What Are Latest Mergers And Acquisitions In The Biologic & Biosimilar RA Drugs Market?

In April 2025, Organon & Co., a US-based healthcare company, acquired regulatory and commercial rights in the United States for TOFIDENCE™, a biosimilar to ACTEMRA® (tocilizumab) for intravenous infusion from Biogen Inc., for an undisclosed amount. With this acquisition, Organon aims to strengthen its immunology and biosimilars portfolio and expand its presence in the U.S. market for rheumatoid arthritis and related autoimmune conditions. Biogen Inc. is a US-based biotechnology company.

Regional Insights

North America was the largest region in the biologic & biosimilar RA drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biologic & Biosimilar RA Drugs Market?

The biologics and biosimilars RA drugs market consists of sales of branded and generic biologics and biosimilar RA drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biologic & Biosimilar RA Drugs Market Report 2026?

The biologic & biosimilar ra drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biologic & biosimilar ra drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.